References
1. Joshi, M.M. and B.R. Garretson, Paclitaxel maculopathy. Arch
Ophthalmol, 2007. 125 (5): p. 709-10.
2. Gore, M.E., et al., Single-agent paclitaxel in patients with
previously untreated stage IV epithelial ovarian cancer. London
Gynaecological Oncology and North Thames Gynaecological Oncology
Groups. Br J Cancer, 1997. 75 (5): p. 710-4.
3. Sekhon, A., et al., Limbal stem cell deficiency secondary to
systemic paclitaxel (Taxol) for breast cancer: a case report. BMC
Ophthalmol, 2020. 20 (1): p. 400.
4. Skolnick, C.A. and D.J. Doughman, Erosive conjunctivitis and
punctal stenosis secondary to docetaxel (taxotere). Eye Contact Lens,
2003. 29 (2): p. 134-5.
5. del Pilar Bernal, M., K. Loftfield, and J.D. Nussdorf,Taxane-induced glaucoma. Lancet, 2000. 355 (9203): p.
577.
6. Seidman, A.D., S. Barrett, and S. Canezo, Photopsia during
3-hour paclitaxel administration at doses > or = 250
mg/m2. J Clin Oncol, 1994. 12 (8): p. 1741-2.
7. Kaya, M., et al., A cross-sectional optical coherence
tomography study in patients on taxane-based therapy and a case report
with the literature review. Cutan Ocul Toxicol, 2020. 39 (3):
p. 287-293.
8. Nomi, N., et al., Indocyanine green angiography findings of
cystoid macular edema secondary to paclitaxel therapy. Jpn J
Ophthalmol, 2018. 62 (2): p. 163-167.
9. Shen, M., L. W.H, and W. H.B, A case of vision loss after the
chemotherapy of cisplatin combined with paclitaxel. Chinese Journal of
New Drugs, 2009. 18 (18): p. 1815-1816.
10. Wall, M.E. and M.C. Wani, Camptothecin and taxol: discovery to
clinic–thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res,
1995. 55 (4): p. 753-60.
11. Weaver, B.A., How Taxol/paclitaxel kills cancer cells. Mol
Biol Cell, 2014. 25 (18): p. 2677-81.
12. Koudelka, S. and J. Turanek, Liposomal paclitaxel
formulations. J Control Release, 2012. 163 (3): p. 322-34.
13. Marupudi, N.I., et al., Paclitaxel: a review of adverse
toxicities and novel delivery strategies. Expert Opin Drug Saf, 2007.6 (5): p. 609-21.
14. Noguchi, Y., et al., Risk Factors for Eye Disorders Caused by
Paclitaxel: A Retrospective Study. Biol Pharm Bull, 2018.41 (11): p. 1694-1700.
15. Alvarez-Fernandez, D., et al., Macular oedema associated with
taxanes: A case report and literature review. Arch Soc Esp Oftalmol,
2020. 95 (10): p. 485-495.
16. Esmaeli, B., et al., Docetaxel-induced histologic changes in
the lacrimal sac and the nasal mucosa. Ophthalmic Plast Reconstr Surg,
2003. 19 (4): p. 305-8.
17. Esmaeli, B., et al., Blockage of the lacrimal drainage
apparatus as a side effect of docetaxel therapy. Cancer, 2003.98 (3): p. 504-7.
18. Yamagishi, T., et al., Epiphora in lung cancer patients
receiving docetaxel: a case series. BMC Res Notes, 2014. 7 : p.
322.
19. Lee, H.S., et al., Bilateral Corneal Epithelial Lesions
Associated with Paclitaxel. Optom Vis Sci, 2016. 93 (10): p.
1333-1336.
20. Hosotani, Y., et al., [A Case of a Corneal Disorder after
Breast Cancer Treatment with Nab-paclitaxel]. Nippon Ganka Gakkai
Zasshi, 2016. 120 (6): p. 449-53.
21. Kuwata, M., et al., Ocular toxicity caused by Paclitaxel in
neonatal sprague-dawley rats. In Vivo, 2009. 23 (4): p. 555-60.
22. Koo, N.K. and Y.C. Kim, A case of paclitaxel-induced
maculopathy treated with methazolamide. Korean J Ophthalmol, 2012.26 (5): p. 394-7.
23. Shih, C.H. and Y.C. Lee, Impaired retinal pigment epithelium
in paclitaxel-induced macular edema: A case report. Medicine
(Baltimore), 2018. 97 (26): p. e11229.
24. Hofstra, L.S., E.G. de Vries, and P.H. Willemse, Ophthalmic
toxicity following paclitaxel infusion. Ann Oncol, 1997.8 (10): p. 1053.
25. Capri, G., et al., Optic nerve disturbances: a new form of
paclitaxel neurotoxicity. J Natl Cancer Inst, 1994. 86 (14): p.
1099-101.
26. Fabre-Guillevin, E., et al., Taxane-induced glaucoma. Lancet,
1999. 354 (9185): p. 1181-2.
27. Scaioli, V., et al., Electrophysiological evaluation of visual
pathways in paclitaxel-treated patients. J Neurooncol, 2006.77 (1): p. 79-87.
28. Agustoni, F., et al., Emerging toxicities in the treatment of
non-small cell lung cancer: ocular disorders. Cancer Treat Rev, 2014.40 (1): p. 197-203.
29. Ehlers, J.P., H. Rayess, and N. Steinle, Topical dorzolamide
therapy for taxane-related macular oedema. Eye (Lond), 2013.27 (1): p. 102-4.
30. Burgos-Blasco, B., et al., Dexamethasone intravitreal implant
in cystoid macular edema secondary to paclitaxel therapy. Am J
Ophthalmol Case Rep, 2020. 18 : p. 100653.
31. Matsuoka, N., et al., Sub-Tenon Injections of Triamcinolone
Acetonide Had Limited Effect on Cystoid Macular Edema Secondary to
Nanoparticle Albumin-Bound-Paclitaxel (Abraxane). Case Rep Ophthalmol
Med, 2015. 2015 : p. 181269.
32. Rahman, H.T., S. Yeh, and C.S. Bergstrom, Cystoid macular
edema without leakage secondary to nab-Paclitaxel (Abraxane): clinical
experience with intravitreal bevacizumab. J Ocul Pharmacol Ther, 2013.29 (3): p. 360-2.
33. Cinici, E., et al., Carvone protects against
paclitaxel-induced retinal and optic nerve cytotoxicity: a
histopathological study. Cutan Ocul Toxicol, 2019. 38 (3): p.
290-293.